This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



ramucirumab (Cyramza®)


Reference No. 2141

Publication date:
29/11/2019


Appraisal information

ramucirumab (Cyramza®) 10 mg/ml concentrate for solution for infusion


Company: Eli Lilly & Co Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 28/11/2019

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, ramucirumab (Cyramza®) cannot be endorsed for use within NHS Wales as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein ≥ 400 ng/mL and who have been previously treated with sorafenib
Statement of Advice (SOA)
Download